AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Invivyd Analyst Reviews: A Comprehensive Look at Ratings and Price Targets
ByAinvest
Tuesday, Aug 19, 2025 8:44 am ET1min read
Invivyd IVVD has received various analyst opinions over the past quarter, with 5 analysts offering a range of ratings from bullish to bearish. The average 12-month price target is $5.0, with a high estimate of $9.00 and a low estimate of $3.00. The current average has decreased by 30.56% from the previous average price target of $7.20. Analysts have made adjustments to their ratings and price targets, with some maintaining their buy rating while others lower it.
Invivyd Inc (IVVD) has experienced a diverse range of analyst opinions over the past quarter, with five analysts providing a spectrum of ratings from bullish to bearish. The average 12-month price target for IVVD stands at $5.00, with a high estimate of $9.00 and a low estimate of $3.00. This average has decreased by 30.56% from the previous average price target of $7.20 [1].Analysts have made adjustments to their ratings and price targets, with some maintaining their buy rating while others have lowered it. For instance, Jason Kolbert of D. Boral Capital maintained his 'Buy' rating but lowered the price target from $9.00 to $3.00 [2]. Similarly, Patrick Trucchio of HC Wainwright & Co. maintained his 'Buy' rating but lowered the price target from $10.00 to $5.00 [2].
The current analyst consensus for IVVD reflects a positive outlook, with a maintained 'Buy' rating and steady price target pointing to future potential. The average target price for IVVD is $4.00, with a high estimate of $5.00 and a low estimate of $3.00. This suggests an upside of 588.35% from the current price of $0.58 [2].
Despite the positive outlook, IVVD reported a quarterly loss of $0.12 per share, compared to the Zacks Consensus Estimate of a loss of $0.04. This represents an earnings surprise of -200.00% [3]. The company also missed revenue estimates by 23.96%, with revenues of $11.79 million for the quarter ended June 2025 compared to year-ago revenues of $2.26 million [3].
Investors should closely monitor management's commentary on the earnings call for insights into the company's future performance. The sustainability of IVVD's stock price will largely depend on how the company's earnings outlook evolves.
References:
[1] https://www.benzinga.com/insights/analyst-ratings/25/08/47205695/demystifying-invivyd-insights-from-5-analyst-reviews
[2] https://www.gurufocus.com/news/3068583/ivvd-analyst-maintains-buy-rating-and-price-target-at-300-ivvd-stock-news
[3] https://finance.yahoo.com/news/invivyd-inc-ivvd-reports-q2-220001647.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet